

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/731,126	12/06/2000	Sheng Lou	6755.US.01

CONFIRMATION NO. 9182

FORMALITIES LETTER



OC000000005920850

Steven F. Weinstock
Abbott Laboratories
D-377 / AP6D-2
100 Abbott Park Road
Abbott Park, IL 60064-6050.

Date Mailed: 03/30/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216

05/31/2001 EABUBAK1 00000028 010025 09731126

01 FC:105 130.00 CH

- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Sm
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



4A

8

\$ Sector

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sheng Lou, et al.

Serial No.: 09/731,126

Filed: December 6, 2000

For: MONOCLONAL ANTIBODIES TO
HUMAN IMMUNODEFICIENCY VIRUS AND
USES THEREOF

Attorney Docket No.: 6755.US.O1

Date: May 23, 2001


Examiner: Unknown

Group Art Unit: 1645

Certificate of Mailing under 37 CFR §1.8(a):
I hereby certify that this paper (along with any
paper referred to as being attached or enclosed) is
being deposited with the United States Postal
Service with sufficient postage as First Class Mail
addressed to as follows:

Assistant Commissioner for Patents
Washington, D.C. 20231

Date of Deposit: May 23, 2001


Linda L. Powell

TRANSMITTAL

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Enclosed herewith for the patent application identified above entitled MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS AND USES THEREOF are the following:

1. Response to Notice to File Missing Parts of Nonprovisional Application, in duplicate (1 Page)
2. Executed Declaration and Power of Attorney for a United States Patent Application (3 Pages)
3. Copy of Notice to File Missing Parts of Nonprovisional Application (2Pages)
4. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR § 1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

ABBOTT LABORATORIES
100 Abbott Park Road
CHAD 0377/AP6D-2
Abbott Park, Illinois 60064-6050
(847) 938-3137 (Telephone)
(847) 938-2623 (Facsimile)

Respectfully submitted,
Sheng Lou, et al.


Dianne Casuto
Registration No. 40,943
Attorney for Applicants